Skip to main content

Maria Llorian Salvador

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Maria Llorian Salvador

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Terapia inmunomoduladora para la retinitis pigmentosa

IP: Maria Llorian Salvador
Collaborators: -
Funding agency: Fundación Lucha contra la Ceguera FUNDALUCE
Funding: 30000
Reference: FUNDALUCE/2024/LLORIAN
Duration: 12/09/2025 - 12/09/2027

Retinal and cognitive dysfunction in type 2 diabetes

IP: Rafael Simó Canonge
Collaborators: Maria Llorian Salvador, Miriam Izquierdo Sans
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 152348.46
Reference: 2022 BP 00067
Duration: 01/04/2024 - 31/03/2027

Topical administration of sitagliptin in experimental models of diabetic retinopathy and glaucoma: delving into mechanisms of action and changing the therapeutic positioning (“Sit@Retina”).

IP: Rafael Simó Canonge
Collaborators: Maria Llorian Salvador
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 321250
Reference: PID2022-138544OB-I00
Duration: 01/09/2023 - 31/08/2026

Ministerio de Ciencia

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Mireia Verdaguer Tremolosa

Mireia Verdaguer Tremolosa

Research technician
General Surgery
Read more
Alvaro Garcia Tornel Garcia Camba

Alvaro Garcia Tornel Garcia Camba

Senior researcher
Stroke research
Read more
Ana Díez Izquierdo

Ana Díez Izquierdo

Main researcher
Growth and Development
Read more
Carina Lera Asensio

Carina Lera Asensio

Research technician
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.